Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy KemPharm (KMPH) stocks in Canada
Learn how to easily invest in KemPharm stocks.
KemPharm is a biotechnology business based in the US. KemPharm stocks (KMPH.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $15 – a decrease of 4.78% over the previous week. KemPharm employs 22 staff and has a trailing 12-month revenue of around $28.4 million.
How to buy shares in KemPharm
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – KMPH – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
- Can I buy shares in KemPharm?
- Has coronavirus impacted KemPharm shares?
- KemPharm shares summary
- Compare share dealing platforms
- Is KemPharm stock a buy or sell?
- KemPharm performance over time
- KemPharm's financials
- How volatile are KemPharm shares?
- Does KemPharm pay a dividend?
- Have KemPharm shares ever split?
- Other common questions
KemPharm stock price (NASDAQ:KMPH)Use our graph to track the performance of KMPH stocks over time.
KemPharm shares at a glance
|Latest market close||$6.17|
|52-week range||$5.86 - $18.15|
|50-day moving average||$8.38|
|200-day moving average||$9.79|
|Wall St. target price||$19.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.95|
Compare online stock trading platforms
Note: The dollar amounts in the table below are in Canadian dollars.
Is it a good time to buy KemPharm stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
KemPharm price performance over time
|1 week (2022-01-20)||-12.23%|
|1 month (2021-12-27)||-33.73%|
|3 months (2021-10-25)||N/A|
|6 months (2021-07-29)||-40.16%|
|1 year (2021-01-29)||2.32%|
|2 years (2020-01-29)||1,414.11%|
|3 years (2019-01-29)||127.68%|
|5 years (2017-01-27)||73.80%|
Is KemPharm under- or over-valued?
Valuing KemPharm stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of KemPharm's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
KemPharm's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $7.6 million.
The EBITDA is a measure of a KemPharm's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$28.4 million|
|Operating margin TTM||25.87%|
|Gross profit TTM||$12 million|
|Return on assets TTM||6.2%|
|Return on equity TTM||-30.85%|
|Market capitalisation||$234.9 million|
TTM: trailing 12 months
KemPharm share dividends
We're not expecting KemPharm to pay a dividend over the next 12 months.
Have KemPharm's shares ever split?
KemPharm's shares were split on a 1:16 basis on 28 December 2020. So if you had owned 16 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your KemPharm shares – just the quantity. However, indirectly, the new 1500% higher share price could have impacted the market appetite for KemPharm shares which in turn could have impacted KemPharm's share price.
KemPharm share price volatility
Over the last 12 months, KemPharm's shares have ranged in value from as little as $5.86 up to $18.15. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while KemPharm's is 3.1485. This would suggest that KemPharm's shares are significantly more volatile than the average for this exchange and represent a higher risk.
KemPharm, Inc. , a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia. KemPharm's lead clinical development candidate for the treatment of stimulant use disorder, KP879, is based on its prodrug of d-methylphenidate, known as serdexmethylphnidate. In addition, the company has received FDA approval for AZSTARYS, a new once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. KemPharm, Inc.
Stocks similar to KemPharm
KemPharm in the news
RBC upgrades Comcast to outperform on subscriber growth
What to watch today: Wall Street to open lower after Nasdaq's worst week since March 2020
Stocks making the biggest moves in the premarket: Kohl's, Snap, Peloton and more
Frequently asked questions
Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.
More guides on Finder
How to buy Nauticus Robotics, Inc. (KITT) stock in Canada when it goes public
Everything we know about the Nauticus Robotics, Inc. IPO, plus information on how to buy in.
What is Mogo and how can you access its new trading platform, MogoTrade? Find out in our review.
Lido’s liquid staking allows investors holding LUNA and less than 32 ETH to reap the rewards of DeFi staking.
Bitcoin Private (BTCP) price, chart, coin profile and news
This guide provides step-by-step instructions on how to buy Bitcoin Private, lists some exchanges where you can get it and provides daily price data on BTCP.
How to buy Haemonetics Corporation stock in Canada
Steps to owning and managing HAE stock, with 24-hour and historical pricing before you buy.
Go Auto Review
Use Go Auto to shop for new or used vehicles from multiple dealerships, with no hidden fees and access to bad credit financing.
How to buy Aritzia stock in Canada
Steps to owning and managing Aritzia (ATZ) stock, with 24-hour and historical pricing before you buy.
CI Direct Trading review
Get low fees and access many different types of accounts, platforms and investments with this reputable online broker.
Hifi Finance (MFT) price prediction
Read our expert analysis on Hifi Finance and how the token will perform in the future.
Kusama (KSM) price prediction
Read our expert analysis on Kusama and how the token will perform in the future.